H.C. Wainwright initiated coverage of Odyssey Therapeutics with a buy rating and a $44 price target, representing roughly 72% upside from the biotech’s last close of $25.62.
The firm highlighted Odyssey’s cash position of $433 million, including $292 million net from its May initial public offering and concurrent private investment in public equity, alongside minimal debt and a current ratio of 11.36. Odyssey is developing precision small molecules and protein therapeutics targeting upstream immune pathways, with its lead asset OD-001—a first-in-class oral RIPK2 scaffolding inhibitor—in Phase 2 trials for ulcerative colitis and Crohn’s disease.
H.C. Wainwright’s price target is the highest among three initiations this week. Oppenheimer assigned an outperform rating with a $40 target, while JPMorgan initiated coverage with an overweight rating and a $26 target. The disparity in targets reflects differing views on trial timelines and commercial potential, though all firms cite OD-001’s mechanism as a key differentiator in the inflammation and immunology market.
Odyssey plans to launch a placebo-controlled Phase 2b monotherapy trial and a Phase 2a combination-induction trial with vedolizumab in the second half of 2026. Interim Phase 2a monotherapy data is expected at UEG Week in October, with topline induction data from both trials slated for the second half of 2027. H.C. Wainwright estimates the company’s cash runway extends through these milestones, including induction readouts projected for 2028.
The analyst, Tyler Van Buren, noted that OD-001 has demonstrated clinical proof-of-concept in ulcerative colitis, positioning Odyssey to address unmet needs in a market dominated by injectable biologics like vedolizumab. The firm’s bullish stance is underpinned by the asset’s potential to reduce inflammation by blocking RIPK2’s recruitment of XIAP, a pathway implicated in multiple inflammatory diseases.
